Pfizer to Withdraw a Cancer Drug Mylotarg


June 22, 2010

The Wall Street Journal

WASHINGTON—The Food and Drug Administration said Monday Pfizer Inc. is withdrawing its cancer drug Mylotarg from the U.S. market after a clinical study showed the drug wasn't effective and had more safety problems.

Mylotarg, marketed by Wyeth until Pfizer bought the company last year, was approved in 2000 as part of FDA's accelerated-approval program. The drug was approved for patients age 60 and older with a type of acute myeloid leukemia, a bone-marrow cancer. About 2,500 patients in the U.S. are treated with the product annually... read more